Status:
COMPLETED
Ketorolac in Breast Cancer Surgery
Lead Sponsor:
Université Catholique de Louvain
Collaborating Sponsors:
Anticancer Fund, Belgium
Conditions:
Curative Breast Cancer Surgery
Inflammatory Positive/Negative Status
Eligibility:
All Genders
18-85 years
Phase:
PHASE3
Brief Summary
Do the use of Ketorolac in one intravenous injection at the moment of the operative incision reduce the number of recurrence in patient with advanced breast cancer without inflammation signs.
Eligibility Criteria
Inclusion
- Written informed Consent age : 18-85 years weight: 50-100 kg Neutrophils / Lymphocytes ratio \>4 and/or "triple negative" histological status and/or Positive lymph nodes
Exclusion
- Previous cancer (behalf of basocellular skin cancer and in situ uterine cervix cancer) Non compliance or refusal of the protocol Positive Pregnancy test Childbearing or breastfeeding mothers Contra-indication for NSAIDs NSAIDs intake in the 5 days before randomisation NSAIDs use planned in the 30 days after randomisation Non curative surgery (T4 or M1 tumor classification )
Key Trial Info
Start Date :
February 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2018
Estimated Enrollment :
203 Patients enrolled
Trial Details
Trial ID
NCT01806259
Start Date
February 1 2013
End Date
September 1 2018
Last Update
April 7 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cliniques universitaires Saint-Luc
Brussels, Belgium, 1200